CN102531893A - 紫草宁肉桂酸酯类衍生物及其合成方法和应用 - Google Patents
紫草宁肉桂酸酯类衍生物及其合成方法和应用 Download PDFInfo
- Publication number
- CN102531893A CN102531893A CN2012100020203A CN201210002020A CN102531893A CN 102531893 A CN102531893 A CN 102531893A CN 2012100020203 A CN2012100020203 A CN 2012100020203A CN 201210002020 A CN201210002020 A CN 201210002020A CN 102531893 A CN102531893 A CN 102531893A
- Authority
- CN
- China
- Prior art keywords
- shikonin
- naphthoquinone
- laurate
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001071917 Lithospermum Species 0.000 title claims abstract description 51
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 title claims abstract description 50
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 title claims abstract description 22
- 241001597008 Nomeidae Species 0.000 title abstract 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 title abstract 2
- 229960001679 octinoxate Drugs 0.000 title abstract 2
- 238000001308 synthesis method Methods 0.000 title 1
- 150000002148 esters Chemical class 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims abstract 2
- -1 shikonin laurate analog Chemical class 0.000 claims description 33
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 2
- 229940070765 laurate Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 10
- 210000004881 tumor cell Anatomy 0.000 abstract description 10
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 abstract description 8
- 229930016911 cinnamic acid Natural products 0.000 abstract description 7
- 235000013985 cinnamic acid Nutrition 0.000 abstract description 7
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 150000001851 cinnamic acid derivatives Chemical class 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000005918 in vitro anti-tumor Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 16
- 238000000034 method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- NQBWNECTZUOWID-QSYVVUFSSA-N cinnamyl cinnamate Chemical group C=1C=CC=CC=1\C=C/C(=O)OC\C=C\C1=CC=CC=C1 NQBWNECTZUOWID-QSYVVUFSSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- NQBWNECTZUOWID-UHFFFAOYSA-N (E)-cinnamyl (E)-cinnamate Natural products C=1C=CC=CC=1C=CC(=O)OCC=CC1=CC=CC=C1 NQBWNECTZUOWID-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- HGEFWFBFQKWVMY-DUXPYHPUSA-N 2,4-dihydroxy-trans cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1O HGEFWFBFQKWVMY-DUXPYHPUSA-N 0.000 description 1
- MEBWABJHRAYGFW-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=C(Cl)C=C1Cl MEBWABJHRAYGFW-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 241001317370 Euchroma Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于化学制药技术领域,具体涉及紫草宁作为先导物的药物设计与抗肿瘤活性相关研究。通过合成手段将系列取代的肉桂酸引入到紫草宁骨架分子中获得相应酯类衍生物,体外抗肿瘤活性研究表明,肉桂酸紫草宁酯类衍生物对肿瘤细胞株有很强的抑制活性。
Description
一:技术领域
本发明属于化学制药技术领域,具体涉及一类紫草宁肉桂酸酯类衍生物的制备及其在肿瘤抑制方面的应用。
二:背景技术
紫草宁具有广谱活性,由于其杀菌活性明显,早期也应用于日用品中。近年来的研究表明,它是一种具有很大潜力的抗肿瘤功能分子。但是由于其脂溶性特点明显,在应用过程中会遇到各种问题,因此,我们希望在紫草宁结构中引入不同的肉桂酸酯类衍生物来改变紫草宁的相关性质,进而解决分子本身存在的弊端。
查阅相关文献发现,该类化合物首次见于Shen Chien-Chang等于2002年在《Journal ofNatural Product》第65期p1857-1862页发表的Antimicrobial Activities of Naphthazarins fromArnebia euchroma(从软紫草中分离的具有抗微生物的萘醌)文章,他们获得了两个以阿卡宁骨架进行修饰的阿卡宁肉桂酸衍生物和3,4-亚甲基二氧肉桂酸基阿卡宁。
最近Zhuo Wen等于2011年在《European Journal of Medicinal Chemistry》第46期p3420-3427页发表Semi-synthesis and antitumor activity of 6-isomers of 5,8-O-dimethyl acylshikoninderivatives(5,8-二甲基乙酰紫草宁的半合成及其抗肿瘤活性研究)的研究论文,他们获得了两个含有肉桂酸结构的紫草宁和3,4-二甲氧基肉桂酸紫草宁,活性结果也表明,该类化合物具有明显的肿瘤细胞抑制活性。
对于紫草宁酯类衍生物,我们曾进行了系列含氟羧酸紫草宁衍生物的制备及活性研究(专利申请号:201110412497.4),发现了具有很好肿瘤细胞抑制活性的功能分子。因此,我们又引入一系列的肉桂酸活性功能分子到紫草宁的结构中,获得了十九种紫草宁肉桂酸衍生物,肿瘤细胞抑制活性结果表明,紫草宁肉桂酸酯类衍生物也是一类非常高效的肿瘤抑制化合物。
三:发明内容
本发明以紫草宁为起始原料,通过合成获得一类新颖的紫草宁肉桂酸酯类抗肿瘤活性功能化合物。本发明的抗肿瘤活性表明,紫草宁肉桂酸酯类衍生物对癌细胞株A875、SW872-S和A549具有明显的抑制活性,其中活性最优的化合物为3,4-二氟肉桂酸紫草宁酯,其IC50值分别达到了0.65,0.69和1.62μmol/mL,其次为三氟甲基肉桂酸紫草宁酯类衍生物,其IC50值也分别达到了0.55,0.36和2.1μmol/mL。
本发明需要解决的问题是提供一类紫草宁肉桂酸酯类衍生物及其制备方法和在肿瘤抑制方面的应用。
本发明的紫草宁酯类衍生物结构通式如式I所示:
式I
式I中的R1所代表的基团分别为下列各项之一:
(1)、式I中R1,R2,R3,R4,R5均为氢原子;
(2)、式I中R3为甲基,R1,R2,R4,R5为氢原子;
(3)、式I中R3为氯原子,R1,R2,R4,R5为氢原子;
(4)、式I中R3为氟原子,R1,R2,R4,R5为氢原子;
(5)、式I中R1为甲基,R2,R3,R4,R5为氢原子;
(6)、式I中R3为三氟甲基,R1,R2,R4,R5为氢原子;
(7)、式I中R1为三氟甲基,R2,R3,R4,R5为氢原子;
(8)、式I中R2为三氟甲基,R1,R3,R4,R5为氢原子;
(9)、式I中R1,R5为氯原子,R2,R3,R4为氢原子;
(10)、式I中R3为甲氧基,R1,R2,R4,R5为氢原子;
(11)、式I中R1为氯原子,R2,R3,R4,R5为氢原子;
(12)、式I中R2为氯原子,R1,R3,R4,R5为氢原子;
(13)、式I中R3为异丙基,R1,R2,R4,R5为氢原子;
(14)、式I中R2为溴原子,R1,R3,R4,R5为氢原子;
(15)、式I中R2为氟原子,R1,R3,R4,R5为氢原子;
(16)、式I中R2,R3为二氟,R1,R4,R5为氢原子;
(17)、式I中R1,R2为二氯,R3,R4,R5为氢原子;
(18)、式I中R1为甲氧基,R2,R3,R4,R6为氢原子;
(19)、式I中R2,R3为二甲氧基,R1,R4,R5为氢原子;
本发明的式I结构紫草宁肉桂酸酯类衍生物是通过紫草宁及相应的取代肉桂酸合成得到的新颖结构功能化合物。
本发明与现有技术相比其有益效果是:
本发明的抗肿瘤活性表明,紫草宁肉桂酸酯类衍生物对癌细胞株A875、SW872-S和A549具有明显的抑制活性,其中活性最优的化合物为3,4-二氟肉桂酸紫草宁酯,其IC50值分别达到了0.65,0.69和1.62μmol/mL,其次为三氟甲基肉桂酸紫草宁酯类衍生物,其IC50值也分别达到了0.55,0.36和2.1μmol/mL。紫草宁具有杀菌、抗肿瘤等活性,在已有发表的文献中,紫草宁的体外肿瘤细胞抑制活性在微摩尔级。在本发明所述系列紫草宁肉桂酸酯类衍生物在与紫草宁相比较过程中,发现3,4-二氟肉桂酸紫草宁酯和对三氟甲基肉桂酸紫草宁酯类衍生物具有明显的肿瘤细胞抑制活性,可制备成抗肿瘤药物。
四:附图说明
图1表示紫草宁肉桂酸酯类衍生物对肿瘤细胞A875的体外活性。
图2表示紫草宁肉桂酸酯类衍生物对肿瘤细胞SW872-S的体外活性。
图3表示紫草宁肉桂酸酯类衍生物对肿瘤细胞A549的体外活性。
五:具体实施方式
实例一:式I类紫草宁肉桂酸酯类衍生物的合成方法
取50mmol的紫草宁和50mmol的相应的肉桂酸溶解在20mL精制二氯甲烷中,于-5℃~0℃继续加入催化剂量的N,N-二环己基碳二亚胺(DCC)和4-二甲氨基吡啶(DMAP),TLC跟踪检测生成相应的酯类衍生物。加入适量硅胶减压浓缩溶剂,以乙酸乙酯∶石油醚=1∶7柱层析,得相应紫草宁羧酸酯类衍生物。
反应以2,4-二氯肉桂酸紫草宁的合成为例:
化合物1
同法可以得到化合物2~21。
相应化合物的理化数据如下:
化合物1:1H NMR(500MHz,CDCl3)δ:12.646(s,1H,-OH);12.458(s,1H,-OH);7.762(d,J=16.0Hz,1H,C=CH-Ar);7.596-7.576(m,2H,Ar-H);7.446-7.434(m,3H,Ar-H);7.217(s,2H,naphthoquinone-H);7.074(s,1H,naphthoquinone-H);6.534(d,J=16.5Hz,1H,CH=C-Ar);6.169(t,J1=5.75Hz,J2=7.0Hz,1H,C-CH=C);5.208(t,J1=7.25Hz,J2=7.0Hz,1H,-CH-C-C=C);2.745-2.704(m,1H,-C-CH2-C=C);2.615-2.571(m,1H,-C-CH2-C=C);1.726(s,3H,C=C-CH3);1.633(s,3H,C=C-CH3).
化合物2:1H NMR(500MHz,CDCl3)δ:12.644(s,1H,-OH);12.459(s,1H,-OH);7.607(d,J=16Hz,1H,C=CH-Ar);7.480(d,J=8Hz,2H,Ar-H);7.242(d,J=8Hz,2H,Ar-H);7.216(s,2H,naphthoquinone-H);7.069(s,1H,naphthoquinone-H);6.484(d,J=15.5Hz,1H,CH=C-Ar);6.159(t,J1=5.75Hz,J2=6.5Hz,1H,C-CH=C);5.206(t,J1=7.25Hz,J2=7.5Hz,1H,-CH-C-C=C);2.739-2.697(m,1H,-C-CH2-C=C);2.608-2.564(m,1H,-C-CH2-C=C);2.416(s,3H,Ar-CH3);1.722(s,3H,C=C-CH3);1.628(s,3H,C=C-CH3).
化合物3:1H NMR(500MHz,CDCl3)δ:12.644(s,1H,-OH);12.458(s,1H,-OH);7.702(d,J=16Hz,1H,C=CH-Ar);7.515(d,J=8.5Hz,2H,Ar-H);7.413(d,J=9Hz,2H,Ar-H);7.216(s,2H,naphthoquinone-H);7.063(s,1H,naphthoquinone-H);6.504(d,J=15.5Hz,1H,CH=C-Ar);6.168(t,J1=5.5Hz,J2=6.5Hz,1H,C-CH=C);5.197(t,J1=7Hz,J2=7.25Hz,1H,-CH-C-C=C);2.751-2.699(m,1H,-C-CH2-C=C);2.611-2.552(m,1H,-C-CH2-C=C);1.723(s,3H,Ar-CH3);1.628(s,3H,C=C-CH3);1.628(s,3H,C=C-CH3).
化合物4:1H NMR(500MHz,CDCl3)δ:12.644(s,1H,-OH);12.454(s,1H,-OH);7.718(d,J=16.5Hz,1H,C=CH-Ar);7.590-7.562(m,2H,Ar-H);7.217(s,2H,naphthoquinone-H);7.130(t,J1=8.75Hz,J2=9Hz,2H,Ar-H);7.064(s,1H,naphthoquinone-H);6.457(d,J=17Hz,1H,CH=C-Ar);6.166(t,J1=5.5Hz,J2=4.5Hz,1H,C-CH=C);5.201(t,J1=6.75Hz,J2=7.5Hz,1H,-CH-C-C=C);2.752-2.700(m,1H,-C-CH2-C=C);2.611-2.566(m,1H,-C-CH2-C=C);1.724(s,3H,Ar-CH3);1.629(s,3H,C=C-CH3);1.628(s,3H,C=C-CH3).
化合物5:1H NMR(500MHz,CDCl3)δ:12.644(s,1H,-OH);12.458(s,1H,-OH);7.702(d,J=16Hz,1H,C=CH-Ar);7.515(d,J=8.5Hz,2H,Ar-H);7.413(d,J=9Hz,2H,Ar-H);7.216(s,2H,naphthoquinone-H);7.063(s,1H,naphthoquinone-H);6.504(d,J=15.5Hz,1H,CH=C-Ar);6.168(t,J1=5.5Hz,J2=6.5Hz,1H,C-CH=C);5.197(t,J1=7Hz,J2=7.25Hz,1H,-CH-C-C=C);2.751-2.699(m,1H,-C-CH2-C=C);2.611-2.552(m,1H,-C-CH2-C=C);1.723(s,3H,Ar-CH3);1.628(s,3H,C=C-CH3);1.628(s,3H,C=C-CH3).
化合物6:1H NMR(500MHz,CDCl3)δ:12.644(s,1H,-OH);12.450(s,1H,-OH);7.766(d,J=16.0Hz,1H,C=CH-Ar);7.692(s,4H,Ar-H);7.218(s,2H,naphthoquinone-H);7.074(s,1H,naphthoquinone-H);6.606(d,J=16.0Hz,1H,CH=C-Ar);6.168(t,J1=5.5Hz,J2=6.5Hz,1H,C-CH=C);5.201(t,J1=7.0Hz,J2=7.0Hz,1H,-CH-C-C=C);2.763-2.711(m,1H,-C-CH2-C=C);2.625-2.580(m,1H,-C-CH2-C=C);1.727(s,3H,C=C-CH3);1.633(s,3H,C=C-CH3).
化合物7:1H NMR(500MHz,CDCl3)δ:12.644(s,1H,-OH);12.458(s,1H,-OH);8.162(d,J=14Hz,1H,C=CH-Ar);7.781(d,J=7.5Hz,1H,C=CH-Ar-H),7.755(d,J=8Hz,1H,C=CH-Ar-H),7.629(t,J1=7.5Hz,J2=7.5Hz,1H,Ar-H);7.540(t,J1=7.75Hz,J2=9.0Hz,1H,Ar-H);7.217(s,2H,naphthoquinone-H);7.060(s,1H,naphthoquinone-H);6.499(d,J=16.0Hz,1H,CH=C-Ar);6.176(t,J1=4.5Hz,J2=5.5Hz,1H,C-CH=C);5.203(t,J1=7.25Hz,J2=7.0Hz,1H,-CH-C-C=C);2.749-2.708(m,1H,-C-CH2-C=C);2.624-2.579(m,1H,-C-CH2-C=C);1.730(s,3H,C=C-CH3);1.636(s,3H,C=C-CH3).
化合物8:1H NMR(500MHz,CDCl3)δ:12.637(s,1H,-OH);12.443(s,1H,-OH);7.828(s,1H,Ar-H);7.770(d,J=16.5Hz,1H,C=CH-Ar);7.747(d,J=6.5Hz,1H,Ar-H);7.687(d,J=7.5Hz,1H,Ar-H);7.571(t,J1=7.5Hz,J2=7.5Hz,1H,Ar-H);7.208(s,2H,naphthoquinone-H);7.075(s,1H,naphthoquinone-H);6.606(d,J=16.0Hz,1H,CH=C-Ar);6.184(t,J1=5.75Hz,J2=6.5Hz,1H,C-CH=C);5.204(t,J1=7.25Hz,J2=7.5Hz,1H,-CH-C-C=C);2.762-2.711(m,1H,-C-CH2-C=C);2.621-2.562(m,1H,-C-CH2-C=C);1.726(s,3H,C=C-CH3);1.623(s,3H,C=C-CH3).
化合物9:1H NMR(500MHz,CDCl3)δ:12.644(s,1H,-OH);12.465(s,1H,-OH);7.900(d,J=16.5Hz,1H,C=CH-Ar);7.397(t,J1=8.0Hz,J2=8.0Hz,3H,Ar-H);7.219(s,2H,naphthoquinone-H);7.089(s,1H,naphthoquinone-H);6.719(d,J=16.5Hz,1H,CH=C-Ar);6.159(t,J1=5.5Hz,J2=6.5Hz,1H,C-CH=C);5.202(t,J1=6.0Hz,J2=7.0Hz,1H,-CH-C-C=C);2.763-2.710(m,1H,-C-CH2-C=C);2.627-2.597(m,1H,-C-CH2-C=C);1.726(s,3H,C=C-CH3);1.630(s,3H,C=C-CH3).
化合物10:1H NMR(500MHz,CDCl3)δ:12.640(s,1H,-OH);12.457(s,1H,-OH);7.712(d,J=16.0Hz,1H,C=CH-Ar);7.534(d,J=9.0Hz,2H,Ar-H);7.213(s,2H,naphthoquinone-H);7.067(s,1H,naphthoquinone-H);6.950(d,J=8.5Hz,2H,Ar-H);6.397(d,J=16.0Hz,1H,CH=C-Ar);6.166-6.144(m,1H,C-CH=C);5.248-5.193(m,1H,-CH-C-C=C);3.979(s,3H,-OCH3);2.748-2.662(m,1H,-C-CH2-C=C);2.604-2.546(m,1H,-C-CH2-C=C);1.723(s,3H,C=C-CH3);1.629(s,3H,C=C-CH3).
化合物11:1H NMR(500MHz,CDCl3)δ:12.638(s,1H,-OH);12.451(s,1H,-OH);8.185(d,J=16.5Hz,1H,C=CH-Ar);7.686(d,J=8.0Hz,1H,Ar-H);7.459(d,J=8.5Hz,1H,Ar-H);7.380-7.308(m,1H,Ar-H);7.211(s,2H,naphthoquinone-H);7.071(s,1H,naphthoquinone-H);6.520(d,J=16.5Hz,1H,CH=C-Ar);6.184-6.160(m,1H,C-CH=C);5.207(t,J1=6.75Hz,J2=6.5Hz,1H,-CH-C-C=C);2.757-2.705(m,1H,-C-CH2-C=C);2.624-2.564(m,1H,-C-CH2-C=C);1.728(s,3H,C=C-CH3);1.641(s,3H,C=C-CH3).
化合物12:1H NMR(500MHz,CDCl3)δ:12.635(s,1H,-OH);12.446(s,1H,-OH);7.683(d,J=16Hz,1H,C=CH-Ar);7.569(s,1H,Ar-H);7.447(d,J=7.0Hz,1H,Ar-H);7.415-7.354(m,2H,Ar-H);7.211(s,2H,naphthoquinone-H);7.062(s,1H,naphthoquinone-H);6.535(d,J=16.0Hz,1H,CH=C-Ar);6.168(t,J1=6.0Hz,J2=7.0Hz,1H,C-CH=C);5.197(t,J1=7.25Hz,J2=7.5Hz,1H,-CH-C-C=C);2.753-2.700(m,1H,-C-CH2-C=C);2.613-2.554(m,1H,-C-CH2-C=C);1.724(s,3H,C=C-CH3);1.628(s,3H,C=C-CH3).
化合物13:1H NMR(500MHz,CDCl3)δ:12.642(s,1H,-OH);12.457(s,1H,-OH);7.741(d,J=16Hz,1H,C=CH-Ar);7.514(d,J=8.0Hz,2H,Ar-H);7.293(d,J=8.5Hz,2H,Ar-H);7.215(s,2H,naphthoquinone-H);7.071(s,1H,naphthoquinone-H);6.486(d,J=16.0Hz,1H,CH=C-Ar);6.168(t,J1=5.75Hz,J2=7.0Hz,1H,C-CH=C);5.205(t,J1=6.5Hz,J2=5.5Hz,1H,-CH-C-C=C);2.993-2.938(m,1H,-C-CH2-C=C);2.741-2.700(m,1H,-C-CH2-C=C);2.609-2.565(m,1H,Ar-CH-C);1.720(s,3H,C=C-CH3);1.628(s,3H,C=C-CH3);1.300(s,3H,Ar-C-CH3);1.286(s,3H,Ar-C-CH3).
化合物14:1H NMR(500MHz,CDCl3)δ:12.633(s,1H,-OH);12.444(s,1H,-OH);7.727(s,1H,Ar-H);7.667(d,J=16Hz,1H,C=CH-Ar);7.554(d,J=8.0Hz,1H,Ar-H);7.487(d,J=8.0Hz,1H,Ar-H);7.306(t,J1=7.75Hz,J2=8.0Hz,1H,C=CH-Ar);7.208(s,2H,naphthoquinone-H);7.059(s,1H,naphthoquinone-H);6.528(d,J=16.0Hz,1H,CH=C-Ar);6.167(m,1H,C-CH=C);5.195(t,J1=6.5Hz,J2=6.0Hz,1H,-CH-C-C=C);2.751-2.699(m,1H,-C-CH2-C=C);2.611-2.552(m,1H,-C-CH2-C=C);1.723(s,3H,C=C-CH3);1.627(s,3H,C=C-CH3).
化合物15:1H NMR(500MHz,CDCl3)δ:12.634(s,1H,-OH);12.444(s,1H,-OH);7.704(d,J=16.5Hz,1H,C=CH-Ar);7.427-7.396(m,1H,Ar-H);7.330(d,J=7.5Hz,1H,Ar-H);7.275(d,J=8.5Hz,1H,Ar-H);7.209(s,2H,naphthoquinone-H);7.152-7.116(m,1H,Ar-H);7.063(s,1H,naphthoquinone-H);6.524(d,J=16.0Hz,1H,CH=C-Ar);6.180-6.158(m,1H,C-CH=C);5.199(t,J1=7.25Hz,J2=7.0Hz,1H,-CH-C-C=C);2.753-2.701(m,1H,-C-CH2-C=C);2.614-2.555(m,1H,-C-CH2-C=C);1.723(s,3H,C=C-CH3);1.630(s,3H,C=C-CH3).
化合物16:1H NMR(500MHz,CDCl3)δ:12.633(s,1H,-OH);12.441(s,1H,-OH);7.648(d,J=16.5Hz,1H,C=CH-Ar);7.427-7.386(m,1H,Ar-H);7.317-7.297(m,1H,Ar-H);7.253-7.215(m,1H,Ar-H);7.210(s,2H,naphthoquinone-H);7.054(s,1H,naphthoquinone-H);6.448(d,J=16.0Hz,1H,CH=C-Ar);6.175-6.152(m,1H,C-CH=C);5.191(t,J1=7.25Hz,J2=7.5Hz,1H,-CH-C-C=C);2.749-2.697(m,1H,-C-CH2-C=C);2.610-2.551(m,1H,-C-CH2-C=C);1.721(s,3H,C=C-CH3);1.625(s,3H,C=C-CH3).
化合物17:1H NMR(500MHz,CDCl3)δ:12.630(s,1H,-OH);12.438(s,1H,-OH);8.168(d,J=15.5Hz,1H,C=CH-Ar);7.578(d,J=8.0Hz,1H,Ar-H);7.528(d,J=7.0Hz,1H,Ar-H);7.288-7.257(m,1H,Ar-H);7.205(s,2H,naphthoquinone-H);7.063(s,1H,naphthoquinone-H);6.501(d,J=15.5Hz,1H,CH=C-Ar);6.168-6.159(m,1H,C-CH=C);5.198(t,J1=7.0Hz,J2=7.0Hz,1H,-CH-C-C=C);2.755-2.703(m,1H,-C-CH2-C=C);2.623-2.564(m,1H,-C-CH2-C=C);1.723(s,3H,C=C-CH3);1.627(s,3H,C=C-CH3).
化合物18:1H NMR(500MHz,CDCl3)δ:12.642(s,1H,-OH);12.461(s,1H,-OH);7.680(d,J=16.0Hz,1H,C=CH-Ar);7.557(dd,J1=1.0Hz,J2=7.5Hz,1H,Ar-H);7.402(m,1H,Ar-H);7.214(s,2H,naphthoquinone-H);7.078(s,1H,naphthoquinone-H);7.008(t,J1=7.5Hz,J2=7.0Hz,1H,Ar-H);6.960(d,J=8.0Hz,1H,Ar-H);6.615(d,J=16.5Hz,1H,CH=C-Ar);6.169-6.147(m,1H,-CH-C-C=C);5.214(t,J1=7.25Hz,J2=7.5Hz,1H,-C-CH=C-C);3.937(s,3H,Ar-OCH3);2.750-2.699(m,1H,-C-CH2-C=C);2.613-2.553(m,1H,-C-CH2-C=C);1.726(s,3H,C=C-CH3);1.641(s,3H,C=C-CH3).
化合物19:1H NMR(500MHz,CDCl3)δ:12.640(s,1H,-OH);12.454(s,1H,-OH);7.697(d,J=15.5Hz,1H,C=CH-Ar);7.212(s,2H,naphthoquinone-H);7.167-7.147(m,1H,Ar-H);7.106(d,J=1.5Hz,1H,Ar-H);7.081(s,1H,naphthoquinone-H);6.909(d,J=9.0Hz,1H,Ar-H);6.397(d,J=16.0Hz1H,C-CH=C);6.166(m,1H,-CH-C-C=C);5.212(t,J1=7.25Hz,J2=7.0Hz,1H,-CH-C-C=C);3.969(s,3H,-OCH3);3.953(s,3H,-OCH3);2.745-2.703(m,1H,-C-CH2-C=C);2.608-2.564(m,1H,-C-CH2-C=C);1.722(s,3H,C=C-CH3);1.625(s,3H,C=C-CH3).
实例二.式I类紫草宁肉桂酸酯衍生物应用
我们对式I类紫草宁肉桂酸衍生物进行了抗肿瘤活性研究,选取肿瘤细胞A875、SW872-S和A549为检测细胞,以MTT法,酶标仪于570nm条件下测定其吸光度并计算OD值。
IC50值计算方法如式所示:
细胞抑制率(%)=(对照组OD值-实验组OD值)/对照组OD值×100%
结果表明,绝大多数紫草宁肉桂酸酯类衍生物在抗肿瘤活性方面具有非常好的抑制作用。相应结果见附图1-3。
三株细胞活性结果表明,紫草宁肉桂酸酯类衍生物对癌细胞株A875、SW872-S和A549具有明显的抑制活性,其中活性最优的化合物为3,4-二氟肉桂酸紫草宁酯,其IC50值分别达到了0.65,0.69和1.62μmol/mL,其次为三氟甲基肉桂酸紫草宁酯类衍生物,其IC50值也分别达到了0.55,0.36和2.1μmol/mL。
本发明所述紫草宁肉桂酸酯类衍生物可制备成抗肿瘤药物。
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100020203A CN102531893A (zh) | 2012-01-05 | 2012-01-05 | 紫草宁肉桂酸酯类衍生物及其合成方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100020203A CN102531893A (zh) | 2012-01-05 | 2012-01-05 | 紫草宁肉桂酸酯类衍生物及其合成方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102531893A true CN102531893A (zh) | 2012-07-04 |
Family
ID=46340081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100020203A Pending CN102531893A (zh) | 2012-01-05 | 2012-01-05 | 紫草宁肉桂酸酯类衍生物及其合成方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102531893A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105153060A (zh) * | 2015-07-10 | 2015-12-16 | 南京大学 | 紫草宁羧酸酯类衍生物及其合成方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101863786A (zh) * | 2010-06-26 | 2010-10-20 | 上海交通大学 | 水溶性紫草素萘茜母核氧烷基化衍生物及其制备和应用方法 |
-
2012
- 2012-01-05 CN CN2012100020203A patent/CN102531893A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101863786A (zh) * | 2010-06-26 | 2010-10-20 | 上海交通大学 | 水溶性紫草素萘茜母核氧烷基化衍生物及其制备和应用方法 |
Non-Patent Citations (2)
Title |
---|
CHIEN-CHANG SHEN ET AL.: "Antimicrobial Activities of Naphthazarins from Arnebia euchroma", 《JOURNAL OF NATURAL PRODUCT》, vol. 65, no. 12, 31 October 2002 (2002-10-31) * |
WEN ZHOU ET AL.: "Semi-synthesis and antitumor activity of 6-isomers of 5,8-O-dimethyl acylshikonin derivatives", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 46, 12 May 2011 (2011-05-12), pages 3420 - 3427 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105153060A (zh) * | 2015-07-10 | 2015-12-16 | 南京大学 | 紫草宁羧酸酯类衍生物及其合成方法和应用 |
CN105153060B (zh) * | 2015-07-10 | 2021-01-29 | 南京大学 | 紫草宁羧酸酯类衍生物及其合成方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gažák et al. | Base-catalyzed oxidation of silybin and isosilybin into 2, 3-dehydro derivatives | |
Verma et al. | Synthesis, antimicrobial and cytotoxicity study of 1, 3-disubstituted-1H-naphtho [1, 2-e][1, 3] oxazines | |
Antoszczak et al. | Synthesis and antiproliferative activity of new bioconjugates of Salinomycin with amino acid esters | |
US9096550B2 (en) | Bryostatin analogues and methods of making and using thereof | |
Moumou et al. | Synthesis and biological evaluation of 9α-and 9β-hydroxyamino-parthenolides as novel anticancer agents | |
Chen et al. | Design, synthesis and antioxidant activity evaluation of novel β-elemene derivatives | |
Dubois et al. | Synthesis of 5 (20) deoxydocetaxel, a new active docetaxel analogue | |
Yan et al. | Solvent-free, microwave assisted synthesis of polyhalo heterocyclic ketene aminals as novel anti-cancer agents | |
Bhalla et al. | One pot, simple, and efficient synthesis of (E)-and (Z)-3-allylidene-β-lactams from 3-allyl-3-phenylseleno-β-lactams: analogues of β-lactamase inhibitors | |
CN103265442A (zh) | 一类新型截短侧耳素衍生物及其制备方法和抗肿瘤用途 | |
Kojima et al. | Structure–activity relationships of hybrid annonaceous acetogenins: powerful growth inhibitory effects of their connecting groups between heterocycle and hydrophobic carbon chain bearing THF ring on human cancer cell lines | |
Marvadi et al. | 5-Chloro-2-thiophenyl-1, 2, 3-triazolylmethyldihydroquinolines as dual inhibitors of Mycobacterium tuberculosis and influenza virus: Synthesis and evaluation | |
CN102531893A (zh) | 紫草宁肉桂酸酯类衍生物及其合成方法和应用 | |
CN102659661A (zh) | 一种紫草宁酯类衍生物的合成方法及应用 | |
EP3088391B1 (en) | Method for producing benzyl ester 2-aminonicotinate derivative | |
KR20130026626A (ko) | 코지산 유도체 제조 방법 | |
Kuranaga et al. | Chemoselective deprotection of silyl ethers by DIBALH | |
CN102659593B (zh) | 紫草宁苯氧羧酸酯类衍生物及其合成方法和应用 | |
RU2168513C2 (ru) | Производные таксана, способ их получения и фармацевтическая композиция | |
CN104829553A (zh) | 一种合成2,4-二取代苯并噻唑的新方法 | |
CN102643247A (zh) | 一类二硫醚类化合物及其制备方法和用途 | |
Abzianidze et al. | Towards lead compounds as anti-cancer agents via new phaeosphaeride A derivatives | |
CN110790707A (zh) | 一种二硫代1,8-萘二酰亚胺类化合物及其制备方法和应用 | |
KR20170066693A (ko) | 포스핀 전이 금속 착체를 함유하는 항암제의 제조 방법 | |
CN105713001A (zh) | 3,3’-二氢呋喃螺环氧化吲哚衍生物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120704 |